Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stimulation modulates cell assemblies linked with gene networks in the human temporal cortex <i>ex vivo</i>.

bioRxiv : the preprint server for biology·2025
Same author

Global health in axial spondyloarthritis: thresholds for the Assessment of SpondyloArthritis international Society Health Index and the EuroQol score: analysis of the ASAS-PerSpA study.

Scandinavian journal of rheumatology·2024
Same author

Single-nucleus and spatial landscape of the sub-ventricular zone in human glioblastoma.

bioRxiv : the preprint server for biology·2024
Same author

Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France.

The Journal of hospital infection·2023
Same author

Annual pulses of copper-enriched sediment in a North American river downstream of a large lake following the catastrophic failure of a mine tailings storage facility.

The Science of the total environment·2022
Same author

Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid.

Talanta·2020

Related Experiment Video

Updated: May 31, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Genetics for understanding and predicting clinical progression in multiple sclerosis.

R Depaz1, B Granger, I Cournu-Rebeix

  • 1Inserm, CNRS, Centre de Recherche de l'Institut Cerveau-Moelle, Hôpital Pitié-Salpêtrière, Université Pierre-et-Marie-Curie Paris-6, UMR 975-7225, 47, Boulevard de l'Hôpital 75013 Paris, France. raphael.de-paz@psl.aphp.fr

Revue Neurologique
|June 21, 2011
PubMed
Summary

Genetic variations may influence multiple sclerosis (MS) clinical outcomes. This review examines epidemiological and association studies to identify potential genetic modifiers for MS, offering insights into new therapeutic targets and prognostic markers.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: May 31, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

  • Neuroimmunology
  • Genetics
  • Epidemiology

Background:

  • Multiple sclerosis (MS) is a complex autoimmune disorder of the central nervous system characterized by unpredictable clinical trajectories.
  • Genetic factors, including HLA alleles and loci identified through Genome Wide Association Studies (GWAS), are known contributors to MS risk.
  • Emerging evidence suggests common genetic variations may modulate MS phenotypes by influencing key pathophysiological pathways.

Purpose of the Study:

  • To review epidemiological and association studies investigating the genetic modifying effects on the clinical phenotype of multiple sclerosis (MS).
  • To explore the potential of identifying modifier genes for novel therapeutic targets and early prognostic markers in MS management.

Main Methods:

  • Systematic review of published epidemiological and genetic association studies.
  • Analysis of data from large patient cohorts to assess the impact of genetic variations on MS clinical outcomes.

Main Results:

  • The role of genetic variations in modulating MS clinical phenotypes is an active area of research.
  • While numerous studies exist, the precise impact of specific modifier genes on MS progression and outcomes remains largely unclear.
  • Large patient cohorts are crucial for robust association studies in this field.

Conclusions:

  • Identification of MS modifier genes holds promise for developing targeted therapies and reliable prognostic tools.
  • Further research utilizing extensive patient data is needed to clarify the complex interplay between genetics and MS clinical presentation.
  • This review synthesizes current knowledge and highlights the need for continued investigation into genetic modifiers for improved MS patient care.